Aptose Biosciences (NASDAQ:APTO) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $23.00 target price on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. Piper Sandler dropped their target price on Aptose Biosciences from $12.00 to $5.00 and set an overweight rating for the company in a research report on Thursday, February 1st. StockNews.com downgraded Aptose Biosciences from a hold rating to a sell rating in a research report on Monday, March 18th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average target price of $19.80.

Aptose Biosciences Price Performance

NASDAQ:APTO opened at $1.50 on Wednesday. The business has a 50 day moving average of $1.83 and a 200 day moving average of $2.35. The company has a market capitalization of $23.58 million, a price-to-earnings ratio of -0.19 and a beta of 1.30. Aptose Biosciences has a 1-year low of $1.36 and a 1-year high of $10.13.

Institutional Trading of Aptose Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in Aptose Biosciences in the fourth quarter valued at approximately $32,000. Sequoia Financial Advisors LLC bought a new stake in Aptose Biosciences in the first quarter valued at approximately $27,000. Annandale Capital LLC lifted its position in Aptose Biosciences by 40.0% in the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 21,334 shares during the last quarter. Cetera Advisors LLC lifted its position in Aptose Biosciences by 40.1% in the fourth quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 24,847 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Aptose Biosciences by 3.6% during the first quarter. Renaissance Technologies LLC now owns 976,577 shares of the biotechnology company’s stock valued at $1,328,000 after buying an additional 33,952 shares during the period. Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.